KR102210935B1 - C형 간염 치료용 2가지 항바이러스제의 병용물 - Google Patents

C형 간염 치료용 2가지 항바이러스제의 병용물 Download PDF

Info

Publication number
KR102210935B1
KR102210935B1 KR1020157029549A KR20157029549A KR102210935B1 KR 102210935 B1 KR102210935 B1 KR 102210935B1 KR 1020157029549 A KR1020157029549 A KR 1020157029549A KR 20157029549 A KR20157029549 A KR 20157029549A KR 102210935 B1 KR102210935 B1 KR 102210935B1
Authority
KR
South Korea
Prior art keywords
weeks
treatment
compound
patient
hcv
Prior art date
Application number
KR1020157029549A
Other languages
English (en)
Korean (ko)
Other versions
KR20150129032A (ko
Inventor
배리 엠. 번스타인
산디프 두타
웨이 류
토마스 제이. 포드사데키
앤드류 엘. 캠벨
라지브 엠. 메논
츠-웨이 린
톈리 왕
왈리드 엠. 오니
Original Assignee
애브비 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50588882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102210935(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 애브비 인코포레이티드 filed Critical 애브비 인코포레이티드
Publication of KR20150129032A publication Critical patent/KR20150129032A/ko
Application granted granted Critical
Publication of KR102210935B1 publication Critical patent/KR102210935B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020157029549A 2013-03-14 2014-03-14 C형 간염 치료용 2가지 항바이러스제의 병용물 KR102210935B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361783376P 2013-03-14 2013-03-14
US61/783,376 2013-03-14
PCT/US2014/027423 WO2014152514A1 (en) 2013-03-14 2014-03-14 Combination of two antivirals for treating hepatitis c

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217002760A Division KR20210013344A (ko) 2013-03-14 2014-03-14 C형 간염 치료용 2가지 항바이러스제의 병용물

Publications (2)

Publication Number Publication Date
KR20150129032A KR20150129032A (ko) 2015-11-18
KR102210935B1 true KR102210935B1 (ko) 2021-02-02

Family

ID=50588882

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157029549A KR102210935B1 (ko) 2013-03-14 2014-03-14 C형 간염 치료용 2가지 항바이러스제의 병용물
KR1020217002760A KR20210013344A (ko) 2013-03-14 2014-03-14 C형 간염 치료용 2가지 항바이러스제의 병용물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217002760A KR20210013344A (ko) 2013-03-14 2014-03-14 C형 간염 치료용 2가지 항바이러스제의 병용물

Country Status (26)

Country Link
US (1) US20140275099A1 (ru)
EP (3) EP2968301B1 (ru)
JP (4) JP6441303B2 (ru)
KR (2) KR102210935B1 (ru)
CN (2) CN108159393A (ru)
AU (2) AU2014239563B2 (ru)
BR (1) BR112015023017B1 (ru)
CA (1) CA2901810C (ru)
CY (2) CY1119025T1 (ru)
DK (2) DK2968301T3 (ru)
EA (2) EA201991174A1 (ru)
ES (2) ES2624980T3 (ru)
HK (2) HK1244668A1 (ru)
HR (2) HRP20171036T1 (ru)
HU (2) HUE052113T2 (ru)
IL (1) IL240419B (ru)
LT (2) LT2968301T (ru)
MX (2) MX362616B (ru)
NZ (2) NZ719137A (ru)
PL (2) PL3213750T3 (ru)
PT (2) PT2968301T (ru)
RS (2) RS56202B1 (ru)
SG (2) SG10201708306WA (ru)
SI (2) SI3213750T1 (ru)
TW (2) TWI686196B (ru)
WO (1) WO2014152514A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201991174A1 (ru) 2013-03-14 2020-01-31 Эббви Инк. Комбинация двух противовирусных препаратов для лечения гепатита c
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US20160317603A9 (en) * 2013-03-14 2016-11-03 Abbvie Inc. Methods for Treating HCV
US20150011481A1 (en) * 2013-07-02 2015-01-08 Abbvie Inc. Methods for Treating HCV
JP2016534082A (ja) * 2013-10-25 2016-11-04 アッヴィ・インコーポレイテッド Ｈｃｖの治療方法
EP3082808A1 (en) * 2013-12-19 2016-10-26 AbbVie Inc. Methods for treating liver transplant recipients
JP6632992B2 (ja) * 2014-04-02 2020-01-22 アッヴィ・インコーポレイテッド Ｈｃｖを処置するための方法
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
AU2016283018C1 (en) * 2015-06-26 2022-03-03 Abbvie Inc. Solid pharmaceutical compositions for treating HCV
JP6808660B2 (ja) * 2015-07-08 2021-01-06 アッヴィ・インコーポレイテッド Ｈｃｖを処置するための方法
JP7133466B2 (ja) * 2015-07-17 2022-09-08 アッヴィ・インコーポレイテッド Ｈｃｖを処置するための固体医薬組成物
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
CA3037719A1 (en) * 2016-09-23 2018-03-29 Abbvie Inc. Dose adjustment
JP2018131439A (ja) * 2017-02-14 2018-08-23 アッヴィ・インコーポレイテッド Ｈｃｖを処置する方法
CA2981993A1 (en) * 2017-08-02 2019-02-02 Abbvie Inc. Methods for treating hcv
TW202012001A (zh) * 2018-04-10 2020-04-01 美商亞堤製藥公司 C型肝炎病毒(hcv)感染硬化之患者的治療
WO2020106835A1 (en) 2018-11-20 2020-05-28 Abbvie Inc. Methods for treating acute hcv
KR102077833B1 (ko) 2018-12-10 2020-02-14 류형준 기능성 식품조성물
CN111688355B (zh) 2019-03-15 2022-04-12 精工爱普生株式会社 液体吸收体、液体吸收器以及液体喷出装置
JP2020172484A (ja) * 2019-04-08 2020-10-22 アッヴィ・インコーポレイテッド Ｈｃｖを治療するための固体医薬組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040167A1 (en) * 2010-09-21 2012-03-29 Enanta Pharmaceuticals, Inc. Macrocyclic proline derived hcv serine protease inhibitors
WO2012051361A1 (en) * 2010-10-13 2012-04-19 Abbott Laboratories Anti-viral compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394279B2 (en) * 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8330139B2 (en) 2011-03-25 2012-12-11 Micron Technology, Inc. Multi-level memory cell
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
PT107924A (pt) 2011-10-21 2014-12-03 Abbvie Inc Tratamento de combinação de daa (eg. com abt-072 ou abt-333) para utilização no tratamento de hcv
HUE046544T2 (hu) * 2012-09-18 2020-03-30 Abbvie Inc Eljárások Hepatitis C kezelésére
EA201991174A1 (ru) 2013-03-14 2020-01-31 Эббви Инк. Комбинация двух противовирусных препаратов для лечения гепатита c

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040167A1 (en) * 2010-09-21 2012-03-29 Enanta Pharmaceuticals, Inc. Macrocyclic proline derived hcv serine protease inhibitors
WO2012051361A1 (en) * 2010-10-13 2012-04-19 Abbott Laboratories Anti-viral compounds

Also Published As

Publication number Publication date
NZ719137A (en) 2017-11-24
CN105073113A (zh) 2015-11-18
EP3766495A1 (en) 2021-01-20
PL2968301T3 (pl) 2017-09-29
AU2016202823A1 (en) 2016-05-19
KR20150129032A (ko) 2015-11-18
EP2968301A1 (en) 2016-01-20
CA2901810A1 (en) 2014-09-25
MX2020005054A (es) 2020-08-20
WO2014152514A1 (en) 2014-09-25
TWI686196B (zh) 2020-03-01
SG11201507364SA (en) 2015-10-29
SI2968301T1 (sl) 2017-07-31
TW201834656A (zh) 2018-10-01
LT2968301T (lt) 2017-05-25
AU2014239563B2 (en) 2016-05-05
JP6441303B2 (ja) 2018-12-19
ES2824473T3 (es) 2021-05-12
EA033257B1 (ru) 2019-09-30
HUE052113T2 (hu) 2021-04-28
HRP20201575T1 (hr) 2020-12-11
SG10201708306WA (en) 2017-11-29
RS56202B1 (sr) 2017-11-30
BR112015023017A2 (pt) 2017-07-18
CY1123387T1 (el) 2021-12-31
BR112015023017B1 (pt) 2022-08-30
MX362616B (es) 2019-01-28
US20140275099A1 (en) 2014-09-18
CN105073113B (zh) 2018-01-02
EP3213750A1 (en) 2017-09-06
RS60881B1 (sr) 2020-11-30
JP2019048868A (ja) 2019-03-28
EA201591702A1 (ru) 2016-09-30
TW201511759A (zh) 2015-04-01
PT2968301T (pt) 2017-07-17
SI3213750T1 (sl) 2020-11-30
ES2624980T3 (es) 2017-07-18
EP2968301B1 (en) 2017-04-19
JP6621902B2 (ja) 2019-12-18
DK2968301T3 (en) 2017-07-24
EA201991174A1 (ru) 2020-01-31
DK3213750T3 (da) 2020-10-19
JP2021130720A (ja) 2021-09-09
AU2016202823B2 (en) 2017-11-23
KR20210013344A (ko) 2021-02-03
IL240419B (en) 2019-03-31
CN108159393A (zh) 2018-06-15
CA2901810C (en) 2019-01-08
EP3213750B1 (en) 2020-08-12
JP2016513695A (ja) 2016-05-16
LT3213750T (lt) 2020-10-26
PL3213750T3 (pl) 2020-12-14
JP2020037589A (ja) 2020-03-12
MX2015012538A (es) 2016-02-10
HUE033010T2 (en) 2017-11-28
HRP20171036T1 (hr) 2017-10-06
HK1223817A1 (zh) 2017-08-11
PT3213750T (pt) 2020-10-19
AU2014239563A1 (en) 2015-08-27
CY1119025T1 (el) 2018-01-10
NZ631155A (en) 2016-05-27
IL240419A0 (en) 2015-09-24
HK1244668A1 (zh) 2018-08-17
TWI642436B (zh) 2018-12-01

Similar Documents

Publication Publication Date Title
JP6621902B2 (ja) Ｃ型肝炎を治療するための２種の抗ウイルス剤の併用
AU2018202581B2 (en) Combination of direct acting antiviral agents and ribavirin for treating HCV patients
AU2015240754B2 (en) Methods for treating HCV
JP6559701B2 (ja) Ｈｃｖを処置するための方法

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
A107 Divisional application of patent
GRNT Written decision to grant